Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene

BACKGROUND: Treatment options in metastatic breast cancer are limited. New therapies preferable with predictive biomarkers are needed. The aim of these trials was to investigate if gene copy number of the topoisomerase 1 gene was predictive of response to the topoisomerase inhibitor irinotecan. METH...

Full description

Saved in:
Bibliographic Details
Published in:BMC Cancer
Main Authors: Kümler, Iben, Balslev, Eva, Stenvang, Jan, Brünner, Nils, Ejlertsen, Bent, Jakobsen, Erik Hugger, Nielsen, Dorte Lisbet
Format: Artigo
Language:Inglês
Published: BioMed Central 2019
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6567440/
https://ncbi.nlm.nih.gov/pubmed/31196001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5788-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items